Abstract
Approximately half a century has passed since the discovery of beta-blockers. Then, their prime therapeutic purpose was to treat angina and cardiac arrhythmias; nowadays, beta-blockers’ usage and effectiveness are extended to treat other cardiovascular diseases, such as hypertension, congestive heart failure, and coronary artery disease. Safety concerns were raised about beta- blockers and their use for chronic obstructive pulmonary disease (COPD) patients with concurrent cardiovascular disease. After thorough research of the literature, this review summarizes the evidence proving that beta-blockers not only might be well tolerated in COPD patients, but they might also have a beneficial effect in this group of patients.
Keywords: Beta-blockers, chronic obstructive pulmonary disease, exacerbations COPD, exacerbations cardiovascular disease, heart failure, lung function.
Graphical Abstract
[1]
Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs-overview and meta-analyses. J Hypertens 2015; 33(2): 195-211.
[http://dx.doi.org/10.1097/HJH.0000000000000447] [PMID: 25485720]
[http://dx.doi.org/10.1097/HJH.0000000000000447] [PMID: 25485720]
[2]
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018; 71(19): e127-248.
[http://dx.doi.org/10.1016/j.jacc.2017.11.006] [PMID: 29146535]
[http://dx.doi.org/10.1016/j.jacc.2017.11.006] [PMID: 29146535]
[3]
Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021-104.
[http://dx.doi.org/10.1093/eurheartj/ehy339] [PMID: 30165516]
[http://dx.doi.org/10.1093/eurheartj/ehy339] [PMID: 30165516]
[4]
Adeloye D, Chua S, Lee C, et al. Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health 2015; 5(2): 020415.
[http://dx.doi.org/10.7189/jogh.05.020415] [PMID: 26755942]
[http://dx.doi.org/10.7189/jogh.05.020415] [PMID: 26755942]
[5]
World Health Organization. Projections of mortality and causes of death. 2015.https://www.who.int/healthinfo/global_burden_disease/projections2015_2030/en/
[6]
Miller J, Edwards LD, Agustí A, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013; 107(9): 1376-84.
[http://dx.doi.org/10.1016/j.rmed.2013.05.001] [PMID: 23791463]
[http://dx.doi.org/10.1016/j.rmed.2013.05.001] [PMID: 23791463]
[7]
Parker CM, Voduc N, Aaron SD, Webb KA, O’Donnell DE. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J 2005; 26(3): 420-8.
[http://dx.doi.org/10.1183/09031936.05.00136304] [PMID: 16135722]
[http://dx.doi.org/10.1183/09031936.05.00136304] [PMID: 16135722]
[8]
Arnett DK, Goodman RA, Halperin JL, Anderson JL, Parekh AK, Zoghbi WA. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U.S. Department of Health and Human Services. J Am Coll Cardiol 2014; 64(17): 1851-6.
[http://dx.doi.org/10.1016/j.jacc.2014.07.012] [PMID: 25219921]
[http://dx.doi.org/10.1016/j.jacc.2014.07.012] [PMID: 25219921]
[9]
Ahmed R, Branley HM. Reversible bronchospasm with the cardio-selective beta-blocker celiprolol in a non-asthmatic subject. Respir Med CME 2009; 2(3): 141-3.
[http://dx.doi.org/10.1016/j.rmedc.2008.10.019]
[http://dx.doi.org/10.1016/j.rmedc.2008.10.019]
[10]
Hawkins NM, Jhund PS, Simpson CR, et al. Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. Eur J Heart Fail 2010; 12(1): 17-24.
[http://dx.doi.org/10.1093/eurjhf/hfp160] [PMID: 19951962]
[http://dx.doi.org/10.1093/eurjhf/hfp160] [PMID: 19951962]
[11]
Kratzer L, Noakes P, Baumwol J, Wrobel JP. Under-utilisation of β-blockers in patients with acute coronary syndrome and comorbid chronic obstructive pulmonary disease. Intern Med J 2018; 48(8): 931-6.
[http://dx.doi.org/10.1111/imj.13795] [PMID: 29573074]
[http://dx.doi.org/10.1111/imj.13795] [PMID: 29573074]
[12]
Mehvar R, Brocks DR. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J Pharm Pharm Sci 2001; 4(2): 185-200.
[PMID: 11466176]
[PMID: 11466176]
[13]
de Boer RA, Voors AA, van Veldhuisen DJ. Nebivolol: third-generation beta-blockade. Expert Opin Pharmacother 2007; 8(10): 1539-50.
[http://dx.doi.org/10.1517/14656566.8.10.1539] [PMID: 17661735]
[http://dx.doi.org/10.1517/14656566.8.10.1539] [PMID: 17661735]
[14]
Jaillon P. Relevance of intrinsic sympathomimetic activity for beta blockers. Am J Cardiol 1990; 66(9): 21C-3C.
[http://dx.doi.org/10.1016/0002-9149(90)90758-S] [PMID: 1977302]
[http://dx.doi.org/10.1016/0002-9149(90)90758-S] [PMID: 1977302]
[15]
Nuttall SL, Routledge HC, Kendall MJ. A comparison of the β1-selectivity of three β1-selective β-blockers. J Clin Pharm Ther 2003; 28(3): 179-86.
[http://dx.doi.org/10.1046/j.1365-2710.2003.00477.x] [PMID: 12795776]
[http://dx.doi.org/10.1046/j.1365-2710.2003.00477.x] [PMID: 12795776]
[16]
Dimmitt SB, Stampfer HG, Warren JB. β-adrenoceptor blockers valuable but higher doses not necessary. Br J Clin Pharmacol 2014; 78(5): 1076-9.
[http://dx.doi.org/10.1111/bcp.12439] [PMID: 24912767]
[http://dx.doi.org/10.1111/bcp.12439] [PMID: 24912767]
[17]
Wong GW, Boyda HN, Wright JM. Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension. Cochrane Database Syst Rev 2016; 3: CD007451.
[http://dx.doi.org/10.1002/14651858.CD007451.pub2] [PMID: 26961574]
[http://dx.doi.org/10.1002/14651858.CD007451.pub2] [PMID: 26961574]
[18]
Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2016; 138(1): 16-27.
[http://dx.doi.org/10.1016/j.jaci.2016.05.011] [PMID: 27373322]
[http://dx.doi.org/10.1016/j.jaci.2016.05.011] [PMID: 27373322]
[19]
Domej W, Oettl K, Renner W. Oxidative stress and free radicals in COPD-implications and relevance for treatment. Int J Chron Obstruct Pulmon Dis 2014; 9: 1207-24.
[http://dx.doi.org/10.2147/COPD.S51226] [PMID: 25378921]
[http://dx.doi.org/10.2147/COPD.S51226] [PMID: 25378921]
[20]
Lee SH, Goswami S, Grudo A, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007; 13(5): 567-9.
[http://dx.doi.org/10.1038/nm1583] [PMID: 17450149]
[http://dx.doi.org/10.1038/nm1583] [PMID: 17450149]
[21]
Ross B, McIntosh M, Rodaros D, Hébert TE, Rohlicek CV. Systemic arterial pressure at maturity in rats following chronic hypoxia in early life. Am J Hypertens 2010; 23(11): 1228-33.
[http://dx.doi.org/10.1038/ajh.2010.160] [PMID: 20671717]
[http://dx.doi.org/10.1038/ajh.2010.160] [PMID: 20671717]
[22]
Müllerova H, Agusti A, Erqou S, Mapel DW. Cardiovascular comorbidity in COPD: systematic literature review. Chest 2013; 144(4): 1163-78.
[http://dx.doi.org/10.1378/chest.12-2847] [PMID: 23722528]
[http://dx.doi.org/10.1378/chest.12-2847] [PMID: 23722528]
[23]
Sidney S, Sorel M, Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128(4): 2068-75.
[http://dx.doi.org/10.1378/chest.128.4.2068] [PMID: 16236856]
[http://dx.doi.org/10.1378/chest.128.4.2068] [PMID: 16236856]
[24]
Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2(1): 8-11.
[http://dx.doi.org/10.1513/pats.200404-032MS] [PMID: 16113462]
[http://dx.doi.org/10.1513/pats.200404-032MS] [PMID: 16113462]
[25]
Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; 4(4): CD003566.
[http://dx.doi.org/10.1002/14651858.CD003566.pub2] [PMID: 16235327]
[http://dx.doi.org/10.1002/14651858.CD003566.pub2] [PMID: 16235327]
[26]
Wunderlich J, Macha HN, Wudicke H, Huckauf H. Beta-adrenoceptor blockers and terbutaline in patients with chronic obstructive lung disease. Effects and interaction after oral administration. Chest 1980; 78(5): 714-20.
[http://dx.doi.org/10.1378/chest.78.5.714] [PMID: 6107217]
[http://dx.doi.org/10.1378/chest.78.5.714] [PMID: 6107217]
[27]
Dorow P, Clauzel AM, Capone P, Mayol R, Mathieu M. A comparison of celiprolol and chlorthalidone in hypertensive patients with reversible bronchial obstruction. J Cardiovasc Pharmacol 1986; 8(Suppl. 4): S102-4.
[http://dx.doi.org/10.1097/00005344-198608004-00022] [PMID: 2427835]
[http://dx.doi.org/10.1097/00005344-198608004-00022] [PMID: 2427835]
[28]
Dorow P, Thalhofer S, Bethge H, Disselhoff G, Wagner G. Long-term treatment of angina pectoris with bisoprolol or atenolol in patients with chronic obstructive bronchitis: a randomized, double-blind crossover study. J Cardiovasc Pharmacol 1990; 16(Suppl. 5): S36-44.
[http://dx.doi.org/10.1097/00005344-199006165-00008] [PMID: 11527135]
[http://dx.doi.org/10.1097/00005344-199006165-00008] [PMID: 11527135]
[29]
Oda N, Miyahara N, Ichikawa H, et al. Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2017; 12: 1119-24.
[http://dx.doi.org/10.2147/COPD.S133071] [PMID: 28435245]
[http://dx.doi.org/10.2147/COPD.S133071] [PMID: 28435245]
[30]
Hawkins NM, MacDonald MR, Petrie MC, et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail 2009; 11(7): 684-90.
[http://dx.doi.org/10.1093/eurjhf/hfp066] [PMID: 19460848]
[http://dx.doi.org/10.1093/eurjhf/hfp066] [PMID: 19460848]
[31]
Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant 2002; 21(12): 1290-5.
[http://dx.doi.org/10.1016/S1053-2498(02)00459-X] [PMID: 12490274]
[http://dx.doi.org/10.1016/S1053-2498(02)00459-X] [PMID: 12490274]
[32]
Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens 2007; 25(4): 731-41.
[http://dx.doi.org/10.1097/HJH.0b013e3280127948] [PMID: 17351362]
[http://dx.doi.org/10.1097/HJH.0b013e3280127948] [PMID: 17351362]
[33]
Lainscak M, Podbregar M, Kovacic D, Rozman J, von Haehling S. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respir Med 2011; 105(Suppl. 1): S44-9.
[http://dx.doi.org/10.1016/S0954-6111(11)70010-5] [PMID: 22015086]
[http://dx.doi.org/10.1016/S0954-6111(11)70010-5] [PMID: 22015086]
[34]
Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol 2010; 55(17): 1780-7.
[http://dx.doi.org/10.1016/j.jacc.2010.01.024] [PMID: 20413026]
[http://dx.doi.org/10.1016/j.jacc.2010.01.024] [PMID: 20413026]
[35]
Light RW, George RB. Serial pulmonary function in patients with acute heart failure. Arch Intern Med 1983; 143(3): 429-33.
[http://dx.doi.org/10.1001/archinte.1983.00350030039007] [PMID: 6830378]
[http://dx.doi.org/10.1001/archinte.1983.00350030039007] [PMID: 6830378]
[36]
Petermann W, Barth J, Entzian P. Heart failure and airway obstruction. Int J Cardiol 1987; 17(2): 207-9.
[http://dx.doi.org/10.1016/0167-5273(87)90132-X] [PMID: 3679602]
[http://dx.doi.org/10.1016/0167-5273(87)90132-X] [PMID: 3679602]
[37]
Pison C, Malo JL, Rouleau JL, Chalaoui J, Ghezzo H, Malo J. Bronchial hyperresponsiveness to inhaled methacholine in subjects with chronic left heart failure at a time of exacerbation and after increasing diuretic therapy. Chest 1989; 96(2): 230-5.
[http://dx.doi.org/10.1378/chest.96.2.230] [PMID: 2666041]
[http://dx.doi.org/10.1378/chest.96.2.230] [PMID: 2666041]
[38]
Minasian AG, van den Elshout FJJ, Dekhuijzen PN, et al. COPD in chronic heart failure: less common than previously thought? Heart Lung 2013; 42(5): 365-71.
[http://dx.doi.org/10.1016/j.hrtlng.2013.07.002] [PMID: 23998385]
[http://dx.doi.org/10.1016/j.hrtlng.2013.07.002] [PMID: 23998385]
[39]
Global initiative for chronic obstructive lung disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD 2019.https://goldcopd.org/wp-content/.../GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf
[40]
Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. β-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170(10): 880-7.
[http://dx.doi.org/10.1001/archinternmed.2010.112] [PMID: 20498416]
[http://dx.doi.org/10.1001/archinternmed.2010.112] [PMID: 20498416]
[41]
Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011; 342: d2549.
[http://dx.doi.org/10.1136/bmj.d2549] [PMID: 21558357]
[http://dx.doi.org/10.1136/bmj.d2549] [PMID: 21558357]
[42]
Bhatt SP, Wells JM, Kinney GL, et al. COPDGene Investigators. β-Blockers are associated with a reduction in COPD exacerbations. Thorax 2016; 71(1): 8-14.
[http://dx.doi.org/10.1136/thoraxjnl-2015-207251] [PMID: 26283710]
[http://dx.doi.org/10.1136/thoraxjnl-2015-207251] [PMID: 26283710]
[43]
Farland MZ, Peters CJ, Williams JD, Bielak KM, Heidel RE, Ray SM. β-Blocker use and incidence of chronic obstructive pulmonary disease exacerbations. Ann Pharmacother 2013; 47(5): 651-6.
[http://dx.doi.org/10.1345/aph.1R600] [PMID: 23585645]
[http://dx.doi.org/10.1345/aph.1R600] [PMID: 23585645]
[44]
Su TH, Chang SH, Kuo CF, Liu PH, Chan YL. β-blockers after acute myocardial infarction in patients with chronic obstructive pulmonary disease: A nationwide population-based observational study. PLoS One 2019; 14(3): e0213187.
[http://dx.doi.org/10.1371/journal.pone.0213187] [PMID: 30835781]
[http://dx.doi.org/10.1371/journal.pone.0213187] [PMID: 30835781]
[45]
McGraw DW, Forbes SL, Mak JC, et al. Transgenic overexpression of beta(2)-adrenergic receptors in airway epithelial cells decreases bronchoconstriction. Am J Physiol Lung Cell Mol Physiol 2000; 279(2): L379-89.
[http://dx.doi.org/10.1152/ajplung.2000.279.2.L379] [PMID: 10926562]
[http://dx.doi.org/10.1152/ajplung.2000.279.2.L379] [PMID: 10926562]
[46]
Callaerts-Vegh Z, Evans KL, Dudekula N, et al. Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci USA 2004; 101(14): 4948-53.
[http://dx.doi.org/10.1073/pnas.0400452101] [PMID: 15069206]
[http://dx.doi.org/10.1073/pnas.0400452101] [PMID: 15069206]
[47]
Matera MG, Calzetta L, Cazzola M. β-Adrenoceptor modulation in chronic obstructive pulmonary disease: present and future perspectives. Drugs 2013; 73(15): 1653-63.
[http://dx.doi.org/10.1007/s40265-013-0120-5] [PMID: 24127222]
[http://dx.doi.org/10.1007/s40265-013-0120-5] [PMID: 24127222]
[48]
Nguyen LP, Omoluabi O, Parra S, et al. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol 2008; 38(3): 256-62.
[http://dx.doi.org/10.1165/rcmb.2007-0279RC] [PMID: 18096872]
[http://dx.doi.org/10.1165/rcmb.2007-0279RC] [PMID: 18096872]
[49]
Bhatt SP, Nanda S, Kintzer JS. Arrhythmias as trigger for acute exacerbations of chronic obstructive pulmonary disease. Respir Med 2012; 106(8): 1134-8.
[http://dx.doi.org/10.1016/j.rmed.2012.04.007] [PMID: 22595809]
[http://dx.doi.org/10.1016/j.rmed.2012.04.007] [PMID: 22595809]
[50]
Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta- analysis of observational studies. PLoS One 2014; 9(11): e113048.
[http://dx.doi.org/10.1371/journal.pone.0113048] [PMID: 25427000]
[http://dx.doi.org/10.1371/journal.pone.0113048] [PMID: 25427000]
[51]
Huang YL, Lai CC, Wang YH, et al. Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD. Int J Chron Obstruct Pulmon Dis 2017; 12: 2987-96.
[http://dx.doi.org/10.2147/COPD.S145913] [PMID: 29066880]
[http://dx.doi.org/10.2147/COPD.S145913] [PMID: 29066880]
[52]
Brooks TW, Creekmore FM, Young DC, Asche CV, Oberg B, Samuelson WM. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers. Pharmacotherapy 2007; 27(5): 684-90.
[http://dx.doi.org/10.1592/phco.27.5.684] [PMID: 17461703]
[http://dx.doi.org/10.1592/phco.27.5.684] [PMID: 17461703]
[53]
Barnett MJ, Milavetz G, Kaboli PJ. beta-Blocker therapy in veterans with asthma or chronic obstructive pulmonary disease. Pharmacotherapy 2005; 25(11): 1550-9.
[http://dx.doi.org/10.1592/phco.2005.25.11.1550] [PMID: 16232018]
[http://dx.doi.org/10.1592/phco.2005.25.11.1550] [PMID: 16232018]
[54]
Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax 2012; 67(11): 977-84.
[http://dx.doi.org/10.1136/thoraxjnl-2012-201945] [PMID: 22941975]
[http://dx.doi.org/10.1136/thoraxjnl-2012-201945] [PMID: 22941975]
[55]
Kubota Y, Asai K, Furuse E, et al. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2015; 10: 515-23.
[http://dx.doi.org/10.2147/COPD.S79942] [PMID: 25784798]
[http://dx.doi.org/10.2147/COPD.S79942] [PMID: 25784798]
[56]
Sessa M, Mascolo A, Mortensen RN, et al. Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study. Eur J Heart Fail 2018; 20(3): 548-56.
[http://dx.doi.org/10.1002/ejhf.1045] [PMID: 29159953]
[http://dx.doi.org/10.1002/ejhf.1045] [PMID: 29159953]
[57]
Sessa M, Mascolo A, Scavone C, et al. Comparison of Long-Term Clinical Implications of Beta-Blockade in Patients With Obstructive Airway Diseases Exposed to Beta-Blockers With Different β1-Adrenoreceptor Selectivity: An Italian Population-Based Cohort Study. Front Pharmacol 2018; 9: 1212.
[http://dx.doi.org/10.3389/fphar.2018.01212] [PMID: 30459608]
[http://dx.doi.org/10.3389/fphar.2018.01212] [PMID: 30459608]
[58]
Liao KM, Lin TY, Huang YB, Kuo CC, Chen CY. The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study. Int J Chron Obstruct Pulmon Dis 2017; 12: 2573-81.
[http://dx.doi.org/10.2147/COPD.S141694] [PMID: 28894360]
[http://dx.doi.org/10.2147/COPD.S141694] [PMID: 28894360]
[59]
Duffy S, Marron R, Voelker H, et al. NIH COPD Clinical Research Network and the Canadian Institutes of Health Research. Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD). Respir Res 2017; 18(1): 124.
[http://dx.doi.org/10.1186/s12931-017-0609-7] [PMID: 28629419]
[http://dx.doi.org/10.1186/s12931-017-0609-7] [PMID: 28629419]
[60]
Dransfield MT, Voelker H, Bhatt SP, et al. BLOCK COPD Trial Group. Metoprolol for the Prevention of Acute Exacerbations of COPD. N Engl J Med 2019; 381(24): 2304-14.
[http://dx.doi.org/10.1056/NEJMoa1908142] [PMID: 31633896]
[http://dx.doi.org/10.1056/NEJMoa1908142] [PMID: 31633896]
[61]
Au DH, Bryson CL, Fan VS, et al. Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am J Med 2004; 117(12): 925-31.
[http://dx.doi.org/10.1016/j.amjmed.2004.07.043] [PMID: 15629731]
[http://dx.doi.org/10.1016/j.amjmed.2004.07.043] [PMID: 15629731]
[62]
Staszewsky L, Wong M, Masson S, et al. Valsartan Heart Failure Trial Investigators. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial. J Card Fail 2007; 13(10): 797-804.
[http://dx.doi.org/10.1016/j.cardfail.2007.07.012] [PMID: 18068611]
[http://dx.doi.org/10.1016/j.cardfail.2007.07.012] [PMID: 18068611]
[63]
Mentz RJ, Wojdyla D, Fiuzat M, Chiswell K, Fonarow GC, O’Connor CM. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol 2013; 111(4): 582-7.
[http://dx.doi.org/10.1016/j.amjcard.2012.10.041] [PMID: 23200803]
[http://dx.doi.org/10.1016/j.amjcard.2012.10.041] [PMID: 23200803]
[64]
Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am J Med 2002; 113(8): 650-6.
[http://dx.doi.org/10.1016/S0002-9343(02)01346-3] [PMID: 12505115]
[http://dx.doi.org/10.1016/S0002-9343(02)01346-3] [PMID: 12505115]
[65]
Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008; 63(4): 301-5.
[http://dx.doi.org/10.1136/thx.2007.081893] [PMID: 17951276]
[http://dx.doi.org/10.1136/thx.2007.081893] [PMID: 17951276]
[66]
Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 2001; 37(7): 1950-6.
[http://dx.doi.org/10.1016/S0735-1097(01)01225-6] [PMID: 11401137]
[http://dx.doi.org/10.1016/S0735-1097(01)01225-6] [PMID: 11401137]
[67]
Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339(8): 489-97.
[http://dx.doi.org/10.1056/NEJM199808203390801] [PMID: 9709041]
[http://dx.doi.org/10.1056/NEJM199808203390801] [PMID: 9709041]
[68]
Hawkins NM, Huang Z, Pieper KS, et al. Valsartan in Acute Myocardial Infarction Trial Investigators. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail 2009; 11(3): 292-8.
[http://dx.doi.org/10.1093/eurjhf/hfp001] [PMID: 19176539]
[http://dx.doi.org/10.1093/eurjhf/hfp001] [PMID: 19176539]
[69]
Coiro S, Girerd N, Rossignol P, et al. Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative. Eur J Heart Fail 2017; 19(2): 271-9.
[http://dx.doi.org/10.1002/ejhf.647] [PMID: 27774703]
[http://dx.doi.org/10.1002/ejhf.647] [PMID: 27774703]
[70]
Andell P, Erlinge D, Smith JG, et al. β-blocker use and mortality in COPD patients after myocardial infarction: a Swedish nationwide observational study. J Am Heart Assoc 2015; 4(4): e001611.
[http://dx.doi.org/10.1161/JAHA.114.001611] [PMID: 25854796]
[http://dx.doi.org/10.1161/JAHA.114.001611] [PMID: 25854796]
[71]
Quint JK, Herrett E, Bhaskaran K, et al. Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ 2013; 347: f6650.
[http://dx.doi.org/10.1136/bmj.f6650] [PMID: 24270505]
[http://dx.doi.org/10.1136/bmj.f6650] [PMID: 24270505]
[72]
Olenchock BA, Fonarow GG, Pan W, Hernandez A, Cannon CP. Get With The Guidelines Steering Committee. Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. Am J Cardiol 2009; 103(3): 295-300.
[http://dx.doi.org/10.1016/j.amjcard.2008.09.081] [PMID: 19166678]
[http://dx.doi.org/10.1016/j.amjcard.2008.09.081] [PMID: 19166678]
[73]
Wang WH, Cheng CC, Mar GY, Wei KC, Huang WC, Liu CP. Improving outcomes in chronic obstructive pulmonary disease by taking beta-blockers after acute myocardial infarction: a nationwide observational study. Heart Vessels 2019; 34(7): 1158-67.
[http://dx.doi.org/10.1007/s00380-019-01341-0] [PMID: 30680495]
[http://dx.doi.org/10.1007/s00380-019-01341-0] [PMID: 30680495]
[74]
van Gestel YR, Hoeks SE, Sin DD, et al. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med 2008; 178(7): 695-700.
[http://dx.doi.org/10.1164/rccm.200803-384OC] [PMID: 18565952]
[http://dx.doi.org/10.1164/rccm.200803-384OC] [PMID: 18565952]
[75]
Angeloni E, Melina G, Roscitano A, et al. β-Blockers improve survival of patients with chronic obstructive pulmonary disease after coronary artery bypass grafting. Ann Thorac Surg 2013; 95(2): 525-31.
[http://dx.doi.org/10.1016/j.athoracsur.2012.07.080] [PMID: 23040827]
[http://dx.doi.org/10.1016/j.athoracsur.2012.07.080] [PMID: 23040827]
[76]
Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med 2012; 12: 48.
[http://dx.doi.org/10.1186/1471-2466-12-48] [PMID: 22947076]
[http://dx.doi.org/10.1186/1471-2466-12-48] [PMID: 22947076]
[77]
Zeng LH, Hu YX, Liu L, Zhang M, Cui H. Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease. Clin Interv Aging 2013; 8: 1157-65.
[PMID: 24072964]
[PMID: 24072964]
[78]
Ekström MP, Hermansson AB, Ström KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187(7): 715-20.
[http://dx.doi.org/10.1164/rccm.201208-1565OC] [PMID: 23328521]
[http://dx.doi.org/10.1164/rccm.201208-1565OC] [PMID: 23328521]
[79]
Ni Y, Shi G, Wan H. Use of cardioselective β-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials. J Int Med Res 2012; 40(6): 2051-65.
[http://dx.doi.org/10.1177/030006051204000602] [PMID: 23321161]
[http://dx.doi.org/10.1177/030006051204000602] [PMID: 23321161]
Article Metrics
20
1